User:Mr. Ibrahem/Enfortumab vedotin

Enfortumab vedotin, sold under the brand name Padcev, is a medication used to treat urothelial carcinoma. It is used in people who have at least advanced disease and have failed other treatments. It is given by gradual injection into a vein.

Common side effects include tiredness, peripheral nerve damage, decreased appetite, rash, hair loss, nausea, altered taste, diarrhea, kidney problems, and low blood cells. Other side effects may include diabetic ketoacidosis, pneumonitis, eye problems, and Stevens-Johnson syndrome. Use during pregnancy may harm the baby. It is a monoclonal antibody attached to vedotin which is a microtubule-disrupting agent. The monoclonal antibody attaches to nectin-4.

Enfortumab vedotin was approved for medical use in the United States in 2019. It is not approved in Europe or the United Kingdom as of 2021. In the United States, for a person who weights 70 kg, the medication costs about 33,400 USD per 4 weeks.